Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations by Marina C. Garassino, MD, Sabine Oskar, PhD, MPH, Ashwini Arunachalam, MPH, BDS, Ke Zu, PhD, ScD, MPH, Yu-Han Kao, PhD, Cai Chen, PhD, Weilin Meng, MEng, M. Catherine Pietanza, MD, Bin Zhao, MD, Himani Aggarwal, MPhil, PhD

Get full text